1. Home
  2. NRIX vs VTEX Comparison

NRIX vs VTEX Comparison

Compare NRIX & VTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • VTEX
  • Stock Information
  • Founded
  • NRIX 2009
  • VTEX 1999
  • Country
  • NRIX United States
  • VTEX Cayman Islands
  • Employees
  • NRIX N/A
  • VTEX N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • VTEX Computer Software: Prepackaged Software
  • Sector
  • NRIX Health Care
  • VTEX Technology
  • Exchange
  • NRIX Nasdaq
  • VTEX Nasdaq
  • Market Cap
  • NRIX 750.4M
  • VTEX 791.5M
  • IPO Year
  • NRIX 2020
  • VTEX 2021
  • Fundamental
  • Price
  • NRIX $12.94
  • VTEX $4.49
  • Analyst Decision
  • NRIX Strong Buy
  • VTEX Strong Buy
  • Analyst Count
  • NRIX 14
  • VTEX 5
  • Target Price
  • NRIX $26.29
  • VTEX $7.16
  • AVG Volume (30 Days)
  • NRIX 1.9M
  • VTEX 1.1M
  • Earning Date
  • NRIX 10-09-2025
  • VTEX 11-06-2025
  • Dividend Yield
  • NRIX N/A
  • VTEX N/A
  • EPS Growth
  • NRIX N/A
  • VTEX 48.79
  • EPS
  • NRIX N/A
  • VTEX 0.05
  • Revenue
  • NRIX $83,687,000.00
  • VTEX $230,497,000.00
  • Revenue This Year
  • NRIX $58.48
  • VTEX $9.30
  • Revenue Next Year
  • NRIX N/A
  • VTEX $13.22
  • P/E Ratio
  • NRIX N/A
  • VTEX $86.12
  • Revenue Growth
  • NRIX 48.32
  • VTEX 4.53
  • 52 Week Low
  • NRIX $8.18
  • VTEX $3.92
  • 52 Week High
  • NRIX $29.56
  • VTEX $6.97
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 70.14
  • VTEX 53.24
  • Support Level
  • NRIX $11.37
  • VTEX $4.28
  • Resistance Level
  • NRIX $13.24
  • VTEX $4.62
  • Average True Range (ATR)
  • NRIX 0.83
  • VTEX 0.16
  • MACD
  • NRIX 0.28
  • VTEX 0.02
  • Stochastic Oscillator
  • NRIX 92.80
  • VTEX 73.35

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

Share on Social Networks: